Instil Bio Inc (TIL)
26.15
+1.39
(+5.61%)
USD |
NASDAQ |
Nov 22, 16:00
25.91
-0.24
(-0.92%)
After-Hours: 20:00
Instil Bio Cash from Financing (Quarterly): 0.159M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.159M |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | -0.587M |
| June 30, 2023 | 4.202M |
| March 31, 2023 | 4.467M |
| December 31, 2022 | 6.202M |
| September 30, 2022 | 14.72M |
| June 30, 2022 | 50.62M |
| Date | Value |
|---|---|
| March 31, 2022 | 0.338M |
| December 31, 2021 | 0.198M |
| September 30, 2021 | 0.121M |
| June 30, 2021 | -1.86M |
| March 31, 2021 | 394.70M |
| December 31, 2020 | 133.07M |
| September 30, 2020 | 0.114M |
| June 30, 2020 | 179.86M |
| March 31, 2020 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.86M
Minimum
Jun 2021
394.70M
Maximum
Mar 2021
41.39M
Average
0.198M
Median
Dec 2021
Cash from Financing (Quarterly) Benchmarks
| Merck & Co Inc | -2.425B |
| Elite Pharmaceuticals Inc | -0.3207M |
| BioCardia Inc | 6.122M |
| Zevra Therapeutics Inc | 64.76M |
| NovaBay Pharmaceuticals Inc | 2.089M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -20.13M |
| Cash from Investing (Quarterly) | 19.81M |
| Free Cash Flow | -68.58M |
| Free Cash Flow Per Share (Quarterly) | -4.631 |
| Free Cash Flow Yield | -40.32% |